Biomarker Optimization Dashboards
Function Health, InsideTracker, Marek - and Biomarker Overreach
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Aggregated lab panels under CLIA; dashboards are not FDA-cleared diagnostic devices
Reference only. Not medical advice.
What can go wrong
Broad asymptomatic screening generates false positives, cascade testing, anxiety, and low-value interventions. 'Optimal' targets unsupported by outcome data can medicalize normal physiology. Hormone-focused dashboards create a direct conduit from a color-coded flag to testosterone therapy without confirmatory morning serum or symptom correlation.
This is something to take to a clinician. The Atlas can tell you what is known about biomarker optimization dashboards in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Biomarker dashboards sell large recurring lab panels with consumer-friendly scoring. Function Health markets ~100+ biomarkers twice yearly with a clinician-reviewed report; InsideTracker markets blood-and-DNA panels with food and supplement recommendations; Marek Health markets hormone panels paired with provider coaching that often lands on optimization. The recurring concern is biomarker overreach: testing many analytes guarantees some fall outside an 'optimal' band by chance, and 'optimal' is frequently narrower than evidence-based reference ranges, nudging healthy users toward supplements, monitoring upsells, or testosterone therapy.
100 biomarkers, an 'optimal' color code, and a path to a prescription.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Users buy a recurring panel; results are mapped onto an 'optimal' color-coded scale and a report (clinician-reviewed to varying degrees). The model monetizes subscriptions, supplement recommendations, and - for hormone-focused brands - downstream therapy. The more analytes measured, the more likely something flags, creating a recurring reason to retest and intervene.
Why 100 biomarkers manufacture findings
If reference ranges are defined so ~5% of healthy people fall outside each analyte by design, testing 100 analytes makes it nearly certain several will read 'abnormal' in a perfectly healthy person - the multiple-comparisons problem. Dashboards compound this by substituting a tighter 'optimal' band for the population range, so even in-range values look deficient. The result is a steady stream of actionable-looking flags that drive supplement sales and, in hormone-focused dashboards, TRT consults. There is little RCT evidence that broad asymptomatic biomarker screening improves outcomes.
What people get wrong
Often saidMore biomarkers equal better health insight
ActuallyWithout outcome evidence, broad asymptomatic panels mainly generate false positives and cascade testing, not better health.
Often said'Optimal' ranges are the real targets
ActuallyDashboard 'optimal' bands are often marketing constructs narrower than evidence-based reference ranges and lacking outcome validation.
Who profits, and who pushes back
H. Gilbert Welch, MD
The more we look in healthy people, the more we find - and most of it does not help them.
Endocrine Society
We recommend against screening for testosterone deficiency in the general asymptomatic population.
What we do not know
- Is there outcome evidence that broad biomarker dashboards improve hard endpoints?
- What fraction of dashboard users with a hormone flag start therapy without confirmatory morning serum?
At a glance
- Function Health panel
- Marketed as ~100+ biomarkers, twice/year
- InsideTracker
- Blood plus DNA, with diet/supplement guidance
- Marek Health
- Hormone panels plus optimization coaching
- Statistical issue
- Many tests guarantee chance out-of-range values
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Biomarker Optimization Dashboards. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Multiple-comparisons / overdiagnosis literatureongoing
Demonstrates that broad testing in low-risk populations yields predictable false positives and cascade care
USPSTF screening principlesongoing
Routine screening is justified by outcome evidence, which broad biomarker panels in healthy adults largely lack
Endocrine Society guideline2018
Advises against population screening for testosterone deficiency in asymptomatic men